The MUT056399 inhibitor of FabI is a new antistaphylococcal compound

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4692-4697

  Escaich, S ^a   Prouvensier, L ^b   Saccomani, M ^b   Durant, L ^b   Oxoby, M ^b   Gerusz, V ^b   Moreau, F ^b   Vongsouthi, V ^b   Maher, Kirsty ^c   Morrissey, Ian ^c   Soulama Mouze, C ^a  

^a FAB pharma   (France)

^b Mutabilis Parc Biocitech   (France)

^c Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; FABI PROTEIN; MUT 056399; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIOSTASIS; CLONING; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BENZAMIDES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FATTY ACID SYNTHETASE COMPLEX, TYPE II; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; OXAZOLIDINONES; PHENYL ETHERS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 80052846256     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01248-10     Document Type: Article

References (44)

1. Altabe, S., P. Lopez, and D. De Mendoza. 2007. Isolation and characterization of unsaturated fatty acid auxotrophs of Streptococcus pneumoniae and Streptococcus mutans. J. Bacteriol. 189:8139-8144. (Pubitemid 350178925)
2. Andes, D., and W. A. Craig. 2003. Pharmacodynamics of the new des-f(6)- quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother. 47:3935-3941.
3. Appelbaum, P. C. 2006. MRSA - the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2):3-10.
4. Appelbaum, P. C. 2007. Reduced glycopeptides susceptibility in methicillinresistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408.
5. Balemans, W., et al. 2010. Essentiality of FASII pathway for Staphylococcus aureus. Nature 463(7279):E3; discussion E4.
6. Brinster, S., et al. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83-86.
7. Bryskier A., et al. 2010. MUT056399: mode of action and mechanisms of resistance, poster F1-832. 50th ICAAC, Boston, MA.
8. Campbell, J. W., and J. E. Cronan. 2001. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55:305-332.
9. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents, M26-A. Vol. 19, no. 18. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A7. Vol. 26, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 7th ed., M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes, M24A. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, M27-A3. Approved standard, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Clinical and Laboratory Standards Institute. 2006. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, M45A. Approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Dangor, Y., R. C. Ballard, S. D. Miller, and H. J. Koornhof. 1990. Antimicrobial susceptibility of Haemophilus ducreyi. Antimicrob. Agents Chemother. 34:1303-1307.
16. De Lassence, A., et al. 2006. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis. 42:170-178. (Pubitemid 43054186)
17. Drew, R. H. 2007. Emerging options for treatment of invasive, multidrugresistant Staphylococcus aureus infections. Pharmacotherapy 27:227-249.
18. Escaich, S., et al. 2009. MUT056399 FabI inhibitor: a new antibacterial candidate against Staphylococcus aureus, poster F1-2012. 49th ICAAC, San Francisco, CA.
19. Gross, M., et al. 2003. Pharmacology of novel heteroaromatic polycycle antibacterials. Antimicrob. Agents Chemother. 47:3448-3457.
20. Heath, R. J., S. W. White, and C. O. Rock. 2001. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 40:467-497.
21. Heath, R. J., S. W. White, and C. O. Rock. 2002. Inhibitors of fatty acidsynthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703.
22. Ji, Y., et al. 2004. Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol. Lett. 231:177-184. (Pubitemid 38251597)
23. Julian, K., et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
24. Karlowsky, J. A., N. Kaplan, B. Hafkin, D. J. Hoban, and G. G. Zhanel. 2009. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob. Agents Chemother. 53:3544-3548.
25. Klein, E., D. L. Smith, and R. Laxminarayan. 2007. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 13:1840-1846.
26. Levy, C. W., et al. 1999. Molecular basis of triclosan activity. Nature 398: 383-384.
27. Ling, L. L., et al. 2004. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob. Agents Chemother. 48:1541-1547.
28. Lu, H., and P. J. Tonge. 2008. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res. 41:11-20.
29. Marrakchi, H., et al. 2003. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem. J. 370:1055-1062.
30. Marrakchi, H., Y. M. Zhang, and C. O. Rock. 2002. Mechanistic diversity and regulation of type II fatty acid synthesis. Biochem. Soc. Trans. 30:1050-1055.
31. Massengo-Tiassé, R. P., and J. E. Cronan. 2009. Diversity in enoyl-acyl carrier protein reductases. Cell. Mol. Life Sci. 66:1507-1517.
32. Moir, D. T. 2005. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord. 5:297-305.
33. Park, H. S., et al. 2007. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J. Antimicrob. Chemother. 60:568-574.
34. Payne, D. J., P. V. Warren, D. J. Holmes, Y. Ji, and J. T. Lonsdale. 2001. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov. Today 6:537-544.
35. Rock, C., M. Frank, and J. Parsons. Metabolic basis for the susceptibility of Gram-positive bacteria to fatty acid synthesis inhibitors, poster F2-864. 50th ICAAC, Boston, MA.
36. Saito, J., et al. 2008. Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor. Protein Sci. 17:691-699.
37. Sampson, P. B., et al. 2009. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI). Bioorg. Med. Chem. Lett. 19:5355-5358.
38. Schmid, N. B., and N. Kaplan. 2004. Reduced triclosan susceptibility in methicillin resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 48:1397-1399. (Pubitemid 38405503)
39. Sivaraman, S., et al. 2004. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem. 47:509-518.
40. Xu, H., et al. 2008. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus. Biochemistry 47:4228-4236. (Pubitemid 351499879)
41. Zhang, Y. M., H. Marrakchi, S. W. White, and C. O. Rock. 2003. The application of computational methods to explore the diversity and structure of bacterial fatty acid synthase. J. Lipid Res. 44:1-10.
42. Zhang, Y. M., and C. O. Rock. 2008. Membrane lipid homeostasis in bacteria. Nat. Rev. Microbiol. 6:222-232.
43. Zhang, Y.-M., S. W. White, and C. O. Rock. 2006. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem. 281:17541-17544.
44. Zheng, C. J., M. J. Sohn, and W. G. Kim. 2009. Vinaxanthone, a new FabI inhibitor from Penicillium sp. J. Antimicrob. Chemother. 63:949-953.